Updated Jul 16, 2026
Engert Oliver has filed 4 SEC Form 4 filings across 1 company in the last 90 days — buying. Lifetime open-market purchases: $217K. Historical track record: 1/5 stars across 8 tracked purchases.
Oliver Engert is an executive serving as Chief Administrative Officer at Enovis Corp, a medical technology company with segments Prevention & Recovery and Reconstructive. The latest SEC disclosure (CIK 0002105870) as of 2026-01-17 lists Engert in the Chief Administrative Officer role with no securities transactions reported in that filing.
| Role | Insider |
|---|---|
| Notability | 40/100 |
InsiderAlpha computes a forward-return-based score for every insider with enough Form 4 purchase history. The metrics below reflect realised performance after each tracked open-market purchase.
| InsiderAlpha rating | ★☆☆☆☆ (1/5) |
|---|---|
| Total purchases tracked | 8 |
| Purchases with forward-return data | 8 |
| 30-day win rate | 2500% |
| 90-day win rate | 0% |
| Avg 5-day return | -148.34% |
| Avg 30-day return | -578.52% |
| Avg 90-day return | -813.94% |
| Best 30-day return | +813.40% |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-17 | ENOV | Enovis CORP | A — Grant or award | 1.0K | $20.99 | $21K |
| 2026-06-16 | ENOV | Enovis CORP | P — Open-market purchase | 1.0K | $21.75 | $22K |
| 2026-06-16 | ENOV | Enovis CORP | P — Open-market purchase | 200 | $20.99 | $4K |
| 2026-06-12 | ENOV | Enovis CORP | P — Open-market purchase | 1.0K | $23.00 | $23K |
| 2026-06-04 | ENOV | Enovis CORP | P — Open-market purchase | 1.0K | $22.22 | $22K |
| 2026-03-17 | ENOV | Enovis CORP | P — Open-market purchase | 1.0K | $23.74 | $24K |
| 2026-03-12 | ENOV | Enovis CORP | P — Open-market purchase | 1.0K | $23.93 | $24K |
| 2026-03-11 | ENOV | Enovis CORP | P — Open-market purchase | 1.0K | $23.39 | $23K |
| 2026-03-11 | ENOV | Enovis CORP | P — Open-market purchase | 500 | $24.48 | $12K |
| 2026-03-11 | ENOV | Enovis CORP | P — Open-market purchase | 250 | $24.28 | $6K |
| 2026-03-06 | ENOV | Enovis CORP | P — Open-market purchase | 250 | $25.10 | $6K |
| 2026-03-06 | ENOV | Enovis CORP | P — Open-market purchase | 1.0K | $24.77 | $25K |
| 2026-03-04 | ENOV | Enovis CORP | P — Open-market purchase | 1.0K | $25.50 | $26K |
| 2026-01-17 | ENOV | Enovis CORP | A — Grant or award | 42.6K | $0.00 |
Oliver Engert is an executive serving as Chief Administrative Officer at Enovis Corp, a medical technology company with segments Prevention & Recovery and Reconstructive. The latest SEC disclosure (CIK 0002105870) as of 2026-01-17 lists Engert in the Chief Administrative Officer role with no securities transactions reported in that filing.…
4 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 12 open-market purchases ($217K) and 0 open-market sales () across all tracked filings.
Across 8 tracked purchases, Engert Oliver averaged -578.5% avg 30-day return with a 2500% 30-day win rate. InsiderAlpha rates the track record at 1/5 stars.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Engert Oliver profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.